#USA #Wilmington #DeepCyte #DeeTox Atlas #AI toxicity

DeepCyte Launches Groundbreaking DeeTox Atlas

In an era where drug safety is paramount, DeepCyte Inc., a pioneering techbio company, has launched the DeeTox Atlas™—the world's first single-cell mechanistic toxicity atlas. This innovative platform is set to transform the landscape of preclinical toxicology by offering predictive insights derived from extensive datasets.

A Deep Dive into DeeTox Atlas™

The DeeTox Atlas is grounded in a proprietary training dataset that encompasses over 300,000 single cells and nearly 100 toxic compounds, analyzed down to approximately 500 metabolites per cellular unit. This ambitious project integrates insights from two independent single-cell metabolomics perturbation studies. For every compound tested, around 3,000 individual measurements were taken across six biological replicas, providing a robust foundation for toxicity predictions.

What makes DeeTox Atlas so innovative is its analytical framework. It categorizes each compound according to a meticulously crafted four-level hierarchy of toxicity mechanisms, anchored in established Adverse Outcome Pathways (AOPs). This structured approach enables the atlas to predict toxicity mechanisms even for compounds that haven’t been specifically measured, making it a powerful tool for toxicologists and safety scientists.

The Implications for Drug Development

DeepCyte's innovative use of AI in toxicology aims to shift the paradigm from reactive laboratory testing to predictive, mechanism-based methodologies. As Theodore Alexandrov, Co-Founder and CEO, articulates, “AI in toxicology relies heavily on the biological data it learns from. DeeTox Atlas allows us to identify subtle molecular patterns that correlate with critical toxicity mechanisms. Our validation studies indicate that these patterns are often present only in small subpopulations of cells, making traditional methods ineffective in capturing them.”

This capability opens new avenues for pharmaceutical companies, enabling them to uncover safety liabilities earlier in the drug discovery process—a pivotal moment when effectiveness and safety are judged.

Future Developments and Expansion

DeepCyte’s commitment to enhancing predictive capabilities goes beyond the initial launch. The DeeTox Atlas is designed for scalability and continuous evolution, with plans to incorporate additional compounds, mechanisms, and assorted biochemical and clinical data, thereby enriching its predictive performance and applicability.

Furthermore, the company has appointed Mona Lakkis as the Senior Vice President of Partnerships. Lakkis, who previously held a leadership role at Owkin, will spearhead the enterprise commercialization efforts for the DeeTox Atlas, aiming to engage with three of the top 20 pharmaceutical companies worldwide. This strategic move underscores DeepCyte’s ambition to position itself as a leader in the predictive toxicology domain.

Conclusion

DeepCyte's launch of DeeTox Atlas signifies a remarkable leap forward in drug development, offering a sophisticated mechanistic understanding of toxicology. By empowering companies with predictive models based on extensive biological data, the atlas is set to play a critical role in paving the way for safer drug development practices. As the pharmaceutical industry increasingly prioritizes safety and efficiency, tools like DeeTox Atlas become indispensable for unlocking new therapeutic potentials while minimizing risks.

With the advent of this technology, the future of drug safety looks brighter than ever, making it an exciting time for both researchers and pharmaceutical companies alike to harness the benefits of AI-driven toxicology.